Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash & Current Investments (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Cash & Current Investments for 4 consecutive years, with $5.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments fell 91.45% year-over-year to $5.7 million, compared with a TTM value of $5.7 million through Sep 2025, down 91.45%, and an annual FY2024 reading of $42.5 million, down 17.84% over the prior year.
  • Cash & Current Investments was $5.7 million for Q3 2025 at Atara Biotherapeutics, down from $22.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $301.8 million in Q1 2022 and bottomed at $5.7 million in Q3 2025.
  • Average Cash & Current Investments over 4 years is $78.5 million, with a median of $48.9 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments increased 3.47% in 2024, then crashed 91.45% in 2025.
  • Year by year, Cash & Current Investments stood at $93.1 million in 2022, then crashed by 44.43% to $51.7 million in 2023, then fell by 17.84% to $42.5 million in 2024, then tumbled by 86.49% to $5.7 million in 2025.
  • Business Quant data shows Cash & Current Investments for ATRA at $5.7 million in Q3 2025, $22.3 million in Q2 2025, and $14.0 million in Q1 2025.